Pfizer's oral Covid-19 antiviral cuts hospitalization, death by 85% (fiercebiotech.com)

Article summary

Pfizer's oral Covid-19 antiviral is reported to cut hospitalization and death by 85%. The discussion revolves around the comparison of this treatment to vaccines in terms of effectiveness and societal impact. The antiviral's ability to reduce severe symptoms is highlighted, while its effect on transmission is debated. The vaccine's role in preventing spread and severe illness is also examined.

Main themes

• Covid-19 treatment comparison
• Vaccine effectiveness
• Transmission and spread
• Herd immunity
• Antiviral treatment benefits
• Vaccine limitations

What commenters say

• Vaccines are effective in reducing severe symptoms and hospitalization, but their impact on transmission is limited.
• The Covid-19 vaccine does reduce the risk of transmission, but not entirely.
• The antiviral treatment may have a comparable individual outcome to vaccines, but its societal impact is different due to the potential for transmission.
• Vaccines are not a silver bullet and their effectiveness wanes over time, especially against new variants.
• The goal of vaccination should be to reduce severe illness and hospitalization, rather than solely focusing on preventing transmission.
• The antiviral treatment and vaccines are not mutually exclusive, and their combined use could be beneficial in reducing the spread and severity of Covid-19.
• The concept of herd immunity through vaccination alone may not be achievable, and other measures are needed to control the spread of the virus.